QIAGEN

CALR is a new cancer biomarker that is mutated in the majority of JAK2 V617F negative cases of Myeloproliferative Neoplasms (MPN), a major form of leukemia... CALR mutations in MPN were just recently discovered in late 2013, but since then there has been increasing evidence for the relevance of CALR in MPN, and its role in MPN subtypes... Currently there is ongoing research for optimized testing algorithms in MPNs using the most relevant molecular markers JAK2 V617F, CALR and MPL. However, CALR research today is usually performed by cumbersome laboratory developed tests (LDTs) using fragment size analysis followed by Sanger sequencing. Lack of a commercially available kit has led to limited CALR research.

Primary location: All United States